Reading OSRH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OSRH free→Reading OSRH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OSRH free→QuarterlyIQ Insights · OSRH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. On June 5, 2026, the Board of Directors of OSR Holdings, Inc. (the “Company”) determined to postpone the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), which had previously been scheduled to be held on June 18, 2026. The Company determined that additional time is necessary to evaluate certain matters relating to the Annual Meeting and the business to be presented to stockholders. Accordingly, the Company believes that postponement of the Annual Meeting is…
Entry into a Material Definitive Agreement. Asset Purchase Agreement On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland. Vaximm is an indirect subsidiary of the Company, and the Asset Purchase Agreement constitutes a related party transaction with respect to the Company. The Asset Purchase Agreement was contemp…
Entry into a Material Definitive Agreement. Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License Agreement”) with BCM Europe AG (“BCME”), the Company’s largest shareholder. Accordingly, the License Agreement constitutes a related party transaction and was approved by the Board, including independent directors, following considerat…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 26, 2026, the Board of Directors (the “Board”) of OSR Holdings, Inc. (the “Company”) approved the appointment of Yeiseok Kim as Chief Operating Officer of the Company, effective April 16, 2026. Mr. Kim, age 36, most recently served as a Senior Analyst at OSR Holdings Co., Ltd., a subsidiary of the Company, from 2020 to 2025, where he suppor…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under “Note Purchase Agreement” and “Senior Secured Convertible Promissory Note” in
Entry into a Material Definitive Agreement. Amendment No. 2 to Common Stock Purchase Agreement On April 7, 2026, OSR Holdings, Inc. (the “Company”) entered into Amendment No. 2 to the Common Stock Purchase Agreement (the “ELOC Amendment”) with White Lion Capital, LLC, d/b/a White Lion GBM Innovation Fund (“White Lion”), which amends that certain Common Stock Purchase Agreement, dated February 25, 2025, as previously amended. The ELOC Amendment introduces additional purchase mechanisms permitt…
Unregistered Sales of Equity Securities. The information set forth in Items 1.01 and 2.03 is incorporated herein by reference. The issuance of the Note and the shares of common stock issuable upon conversion thereof were made in reliance upon exemptions from registration under the Securities Act of 1933, as amended, including Section 4(a)(2) and/or Rule 506 of Regulation D. White Lion represented that it is an accredited investor, and the securities were issued without general solicitation or…
Entry into a Material Definitive Agreement On March 27, 2026, OSR Holdings, Inc. (the “Company” or “OSRH”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”) relating to a revised global exclusive license arrangement for VXM01. The Term Sheet supersedes and replaces in its entirety the prior binding term sheet dated January 13, 2025 between Vaximm and BCME. Under the revised structure, the Company h…
contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express Company management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard On March 5, 2026, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00…
Completion of Acquisition or Disposition of Assets On January 26, 2026 (the “Closing Date”), OSR Holdings Co., Ltd. (“OSRK”), a subsidiary of OSR Holdings, Inc. (the “Company”), completed the share exchange transaction contemplated by the Share Exchange Agreement dated October 13, 2025 (the “Share Exchange Agreement”), by and among OSRK and Woori IO Co., Ltd. (“WORIO”), a South Korea-based medical device company developing non-invasive biosensing technology for glucose monitoring and related…
Entry into a Material Definitive Agreement On January 13, 2025, Vaximm AG, a wholly-owned subsidiary of OSR Holdings, Inc. (the “Company”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”), the largest shareholder of the Company, relating to a proposed global exclusive license of Vaximm’s VXM01 oral cancer immunotherapy platform. The Term Sheet supersedes and replaces in its entirety the prior non-binding term sheet dated November 21, 2025. Pursuant to the Term…
Entry into a Material Definitive Agreement. On October 13, 2025, OSR Holdings Co., Ltd. (“OSRK”), a wholly owned subsidiary of OSR Holdings Inc. (NASDAQ: OSRH, the “Company”), entered into a Share Exchange Agreement (the “Agreement”) with Woori IO Co., Ltd. (“WORIO”). Under the Agreement, OSRK will acquire all issued and outstanding shares of WORIO through a comprehensive share exchange under the Korean Commercial Act, and WORIO will become a wholly owned subsidiary of OSRK and indirectly of…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 5, 2025, OSR Holdings, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock has been below $1.00 per share for…
Entry into a Material Definitive Agreement. On August 10, 2025, OSR Holdings, Inc. (the “Company”) entered into the following amendment agreements with White Lion Capital, LLC, dba White Lion GBM Innovation Fund (“White Lion”): Amendment No. 1 to Note Purchase Agreement The Company and White Lion entered into Amendment No. 1 to the Note Purchase Agreement, originally dated May 6, 2025. The amendment replaces Section 5(f) of the Note Purchase Agreement in its entirety to require the Company to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On June 26, 2025, Sang Hyun Kim provided notice of his resignation as a member of the Board of Directors (the “Board”), including his role as an independent director of OSR Holdings, Inc. (the “Company”). Mr. Kim’s resignation took immediate effect and was not the result of any dispute or disagreement with the Company on any matter relating to its op…
Entry into a Material Definitive Agreement. Note Purchase Agreement On May 6, 2025, OSR Holdings, Inc. (the “ Company ”) entered into a Note Purchase Agreement with White Lion Capital, LLC, dba White Lion GBM Innovation Fund, a Nevada limited liability company (the “ Buyer ”). Convertible Note Pursuant and subject to the terms of the Note Purchase Agreement, the Selling Stockholder has loaned the Company the principal amount of $1,110,000 at an interest rate of 5% per annum subject to two Con…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (c) Appointment of Chief Scientific Officer On March 24, 2025, the Board of Directors of OSR Holdings, Inc. (the “Company”) appointed Dr. Constance Höfer as the Company’s Chief Scientific Officer , effective immediately. Dr. Höfer is a seasoned leader in drug development with over 20 years of experience in oncology and immunology and will oversee OS…
Entry into a Material Definitive Agreement. Common Stock Purchase Agreement On February 25, 2025, OSR Holdings, Inc. (the “Company”) entered into a common stock purchase agreement (the “Common Stock Purchase Agreement”) and a related registration rights agreement (the “White Lion RRA”) with White Lion GBM Innovation Fund (“White Lion”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Common Stock Purchase Agreement. Pursuant to the Common St…
Unregistered Sales of Equity Securities. The information contained in
Other Events. Closing of Business Combination On February 14, 2025, OSR Holdings, Inc., formerly known as Bellevue Life Sciences Acquisition Corp., issued a press release announcing the closing of its previously announced business combination with OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea. A copy of the press release is attached as Exhibit 99.1 hereto.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Promissory Note Amendments As previously disclosed by Bellevue Life Sciences Acquisition Corp. (the “ Company ”) in its Current Reports on Form 8-K filed with the Securities and Exchange Commission on (i) April 11, 2024, (ii) April 22, 2024, (iii) May 14, 2024, and (iv) July 16, 2024, the Company issued unsecured promissory notes (each, a “ Promissory Note ” and, collectively, th…
Entry into a Material Definitive Agreement. The information provided in
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'None' to 'mixed'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.